Information Provided By: 
Fly News Breaks for April 30, 2015
ZGNX
Apr 30, 2015 | 07:46 EDT
Leerink believes the risk/reward for shares of Zogenix is favorable ahead of the ZX008 data in mid-2016. Following its analysis of ZX008 in epilepsy, Leerink is "intrigued by patient/investigator anecdotes on the drug's significant anti-convulsive impact in various seizure types." The firm reiterates an Outperform rating on the stock with a $3 price target.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
